Synaptogenix Inc (SNPX)

[SF Wolf]

AF is mildly critical of NTRP but really kicks AVXL in the gut:

Adam Feuerstein
Follow
Mar 24, 2017 8:34 AM EDT

Michael A. "Hi Adam, with the Eli Lilly (LLY) solanezumab flop now four months behind us and several readouts for different molecules targeting other Abeta intervention points expected later this year. What is your expectation in the field going forward?"

Bleak. Be wary of anyone offering rosy assessments of effective Alzheimer's drugs. Unicorns are easier to find. Lilly's sola failure last December was followed in February by the forced halt to Merck's (MRK) verubecestat phase III study due to futility at an interim analysis.

Coming up in the third quarter, Axovant Sciences (AXON) will announce results from its phase III study of intepiridine. Risky? Absolutely, given the spotty track record for 5-HT6 antagonists in Alzheimer's.

Beyond Axovant, the Alzheimer's field gets far more murky. Companies like Neurotrope (NTRP) and Anavex Life Sciences (AVXL) are best known for making unsubstantiated drug claims based on fringe science. A phase II study of Neurotrope's bryostatin in patients with moderate to severe Alzheimer's reads out in April. I wrote about bryostatin here.

Anavex uses rehashed, recycled data on Anavex 2-73 to help sell stock to a vulture finance fund, which in turn offloads shares to retail investors. The company says a larger, scientifically rigorous study of the drug is in the planning stages, but actual execution seems to be kicked down the road on a regular basis.
https://www.thestreet.com/story/14058387/1/biotech-stock-mailbag-sage-therapeutics-cellceutix-alzheimer-s-risk.html